Prostatectomy

• 

  Subject Areas on Research

  • A 66-year-old man with prostate-specific antigen recurrence and lung mass after radical prostatectomy. 
  • A Case of Fatal Clostridial Necrotizing Fasciitis After Radical Prostatectomy. 
  • A Comparison of Perioperative Outcomes Between Single-port and Multiport Robot-assisted Laparoscopic Prostatectomy. 
  • A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI). 
  • A Novel Expert Coaching Model in Urology, Aimed at Accelerating the Learning Curve in Robotic Prostatectomy. 
  • A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2). 
  • A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group. 
  • A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. 
  • A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer. 
  • A longitudinal assessment of bowel related symptoms and fecal incontinence following radical perineal prostatectomy. 
  • A novel neoplastic primary tumor-derived human prostate epithelial cell line. 
  • A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. 
  • A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. 
  • A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. 
  • A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy. 
  • A single-institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database. 
  • Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. 
  • Acute Presentation of Previously Unrecognized Congenital Ureteropelvic Junction Obstruction 5 Weeks After Radical Retropubic Prostatectomy. 
  • Adenocarcinoma of the prostate. I. Tissue sampling considerations. 
  • Adenocarcinoma of the prostate. Part II: Tissue prognosticators. 
  • Adenocarcinoma of the prostate: an expensive way to die. 
  • Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. 
  • Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. 
  • Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. 
  • Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. 
  • Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. 
  • Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. 
  • Advanced topics in evidence-based urological oncology: using results of a subgroup analysis. 
  • Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted? 
  • African American Men With Low-Risk Prostate Cancer Are Candidates for Active Surveillance: The Will-Rogers Effect? 
  • African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance. 
  • After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. 
  • Agent Orange and long-term outcomes after radical prostatectomy. 
  • An Assessment of Patient Comfort and Morbidity After Robot-Assisted Radical Prostatectomy with Suprapubic Tube Versus Urethral Catheter Drainage. 
  • An important goal of prostatectomy: minimizing incontinence. 
  • Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. 
  • Anastomotic contracture and incontinence after radical prostatectomy: a graded approach to management. 
  • Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. 
  • Apical soft tissue biopsies predict biochemical failure in radical perineal prostatectomy patients with apical cancer involvement. 
  • Apical surgical margins status in robot-assisted laparoscopic radical prostatectomy does not depend on disease characteristics. 
  • Apparent Diffusion Coefficient Values of the Benign Central Zone of the Prostate: Comparison With Low- and High-Grade Prostate Cancer. 
  • Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. 
  • Assessing adverse events of postprostatectomy radiation therapy for prostate cancer: evaluation of outcomes in the Regione Emilia-Romagna, Italy. 
  • Assessment after focal therapy: what is the latest? 
  • Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors. 
  • Association between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes among Patients with Intermediate and High-Risk Localized Prostate Cancer. 
  • Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database. 
  • Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. 
  • Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. 
  • Association of cigarette smoking with interval to biochemical recurrence after radical prostatectomy: results from the SEARCH database. 
  • B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. 
  • Benign prostatic hyperplasia. New concepts in the 1990s. 
  • Benign prostatic hyperplasia: diagnosis and treatment. Benign Prostatic Hyperplasia Guideline Panel. Agency for Health Care Policy and Research. 
  • Bilateral focal ablation of prostate tissue using low-energy direct current (LEDC): a preclinical canine study. 
  • Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. 
  • Biochemical recurrence of prostate cancer. 
  • Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. 
  • Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. 
  • Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. 
  • Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. 
  • Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. 
  • CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. 
  • Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer? 
  • Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer? 
  • Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. 
  • Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. 
  • Capromab Pendetide imaging of prostate cancer. 
  • Case profile: unusual complications of radical perineal prostatectomy. 
  • Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. 
  • Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. 
  • Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. 
  • Characteristics of Detected and Missed Prostate Cancer Foci on 3-T Multiparametric MRI Using an Endorectal Coil Correlated With Whole-Mount Thin-Section Histopathology. 
  • Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy. 
  • Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database. 
  • Clinical characteristics of African-American men with hereditary prostate cancer: the AAHPC Study. 
  • Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. 
  • Clinically detected carcinoma of the prostate treated by radical prostatectomy in a 29-year-old man. 
  • Clinically localized prostatic carcinoma. 
  • Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. 
  • Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. 
  • Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy. 
  • Comparing radical prostatectomy and brachytherapy for localized prostate cancer. 
  • Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. 
  • Comparison of Cost and Perioperative Outcomes Among Patients Undergoing Simple Prostatectomy and Laser Enucleation of the Prostate. 
  • Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy. 
  • Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. 
  • Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. 
  • Comparison of ultrasound-guided biopsies and prostatectomy specimens: predictive accuracy of Gleason score and tumor site. 
  • Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy. 
  • Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients. 
  • Complications of laparoscopic surgery for urological cancer: a single institution analysis. 
  • Comprehensive preoperative evaluation and repair of inguinal hernias at the time of open radical retropubic prostatectomy decreases risk of developing postprostatectomy hernia. 
  • Concordance in the perception of couples recovering from primary surgical treatment of prostate cancer. 
  • Contemporary management of postprostatectomy incontinence. 
  • Controversies in the treatment of prostate cancer with maximal androgen deprivation. 
  • Cost comparison of radical retropubic and radical perineal prostatectomy: single institution experience. 
  • Cost effectiveness of treatment strategies for high risk prostate cancer. 
  • Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer. 
  • Cost-effectiveness of Robotic-Assisted Prostatectomy in the UK-Are We Doing Enough? 
  • Counterpoint: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Most Men With Clinically Important Localized Prostate Cancer Deserve First-Line Open or Robotic Radical Prostatectomy. 
  • Critical review of radical cystectomy and indicators of prognosis. 
  • Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. 
  • DNA in radical prostatectomy specimens. Prognostic value of tumor ploidy. 
  • Defining the Incremental Utility of Prostate Multiparametric Magnetic Resonance Imaging at Standard and Specialized Read in Predicting Extracapsular Extension of Prostate Cancer. 
  • Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? 
  • Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. 
  • Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. 
  • Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. 
  • Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. 
  • Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy. 
  • Disparate results between proliferation rates of surgically excised prostate tumors and an in vitro bioassay using sera from a positive randomized controlled trial. 
  • Do Hispanic Men Have Worse Outcomes After Radical Prostatectomy? Results From SEARCH. 
  • Does Any Racial Disparity Exist in Oncologic Outcomes After Primary Cryotherapy for Prostate Cancer? A Matched-pair Comparative Analysis of the Cryo On-Line Data Registry. 
  • Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group. 
  • Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial. 
  • Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database. 
  • Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance? 
  • Does preoperative topical antimicrobial scrub reduce positive surgical site culture rates in men undergoing artificial urinary sphincter placement? 
  • Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy? 
  • Does prostate transitional cell carcinoma preclude orthotopic bladder reconstruction after radical cystoprostatectomy for bladder cancer? 
  • Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy? 
  • Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival? 
  • Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer? 
  • Does transurethral resection of the prostate promote metastatic disease? 
  • Dynamic prediction of metastases after radical prostatectomy for prostate cancer. 
  • Early prostate cancer: prevention, treatment modalities, and quality of life issues. 
  • Early salvage versus adjuvant therapy for treatment of prostate cancer following prostatectomy. 
  • Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. 
  • Editorial Comment. 
  • Editorial Comment. 
  • Editorial Comment. 
  • Editorial comment. 
  • Editorial comment. 
  • Editorial comment. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--Implications for a risk-adapted follow-up strategy. 
  • Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. 
  • Effect of positive end-expiratory pressure on blood loss during retropubic and robot-assisted laparoscopic radical prostatectomy. 
  • Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer. 
  • Effects of physical and mental health on relationship satisfaction: a dyadic, longitudinal examination of couples facing prostate cancer. 
  • Endoscopic management of the obliterated anastomosis following radical prostatectomy. 
  • Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. 
  • Episode-based Payment Variation for Urologic Cancer Surgery. 
  • Erectile function outcome reporting after clinically localized prostate cancer treatment. 
  • Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy. 
  • External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence. 
  • External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: results from the Duke Prostate Center Database. 
  • Extraperitoneal versus Transperitoneal Single Port Robotic Radical Prostatectomy: A Comparative Analysis of Perioperative Outcomes. 
  • Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database. 
  • Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy. 
  • Factors predicting prostatic biopsy Gleason sum under grading. 
  • Family history of prostate cancer and relapse after definitive external beam radiation therapy. 
  • Financial Margins for Prostate Cancer Surgery: Quantifying the Impact of Modifiable Cost Inputs in an Episode Based Reimbursement Model. 
  • Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. 
  • Fine-tuning robot-assisted radical prostatectomy planning with MRI. 
  • First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. 
  • First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH. 
  • Fitting NTCP models to bladder doses and acute urinary symptoms during post-prostatectomy radiotherapy. 
  • Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial. 
  • Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy. 
  • Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. 
  • Focal therapy for prostate and renal cancer--are we ready for it? 
  • Focal therapy for prostate cancer: possibilities and limitations. 
  • For incontinence after prostatectomy, tap a diversity of treatments. 
  • Gossypiboma (retained surgical sponge) and recurrent bladder neck contracture after radical retropubic prostatectomy and bilateral pelvic lymph node dissection. 
  • Guideline for the management of clinically localized prostate cancer: 2007 update. 
  • High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. 
  • High-Risk Prostate Cancer: Role of Radical Prostatectomy and Radiation Therapy. 
  • High-risk prostate cancer and radical prostatectomy in the setting and context of multidisciplinary care. 
  • Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy. 
  • Identification and characterization of proximal 6q deletions in prostate cancer. 
  • Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer. 
  • Impact of Acetazolamide on Perioperative Pain Control in Robotic Assisted Laparoscopic Prostatectomy. 
  • Impact of Parkinson's disease on continence after radical prostatectomy. 
  • Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. 
  • Impact of comorbidity on health-related quality of life after prostate cancer treatment: combined analysis of two prospective cohort studies. 
  • Impact of diagnosis and treatment of clinically localized prostate cancer on health-related quality of life for older Americans: a population-based study. 
  • Impact of pelvic lymphadenectomy in patients with prostatic adenocarcinoma. 
  • Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. 
  • Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. 
  • Impact of race on survival in men with metastatic hormone-refractory prostate cancer. 
  • Impact of radical prostatectomy in the management of clinically localized disease. 
  • Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. 
  • Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma. 
  • Increased optical magnification from 2.5x to 4.3x with technical modification lowers the positive margin rate in open radical retropubic prostatectomy. 
  • Inferior vena cava compression due to massive hydronephrosis from bladder outlet obstruction. 
  • Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. 
  • Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. 
  • Influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer with established capsular penetration. 
  • Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. 
  • Initiation of salvage therapy for prostate cancer. 
  • Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. 
  • International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. 
  • International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. 
  • International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. 
  • International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. 
  • International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. 
  • Interrupted versus Continuous Suturing for Vesicourethral Anastomosis During Radical Prostatectomy: A Systematic Review and Meta-analysis. 
  • Intratumoral inflammation is associated with more aggressive prostate cancer. 
  • Intraurethral catheter placement does not change the external circumferential measurement of the urethra during AUS placement: A prospective observational trial. 
  • Investigating the heterogeneity of viscoelastic properties in prostate cancer using MR elastography at 9.4T in fresh prostatectomy specimens. 
  • Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study. 
  • Is grade or stage of primary importance in determining the outcome after radical prostatectomy for disease clinically confined to the prostate? 
  • Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. 
  • Is radical prostatectomy appropriate for very-high-risk prostate cancer patients? No. 
  • Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. 
  • Laparoscopic inguinal hernia repair complicates future pelvic oncologic surgery. 
  • Laparoscopic radical prostatectomy in the canine model. 
  • Laparoscopy-assisted robotic radical cystoprostatectomy with ileal conduit urinary diversion for muscle-invasive bladder cancer: initial two cases. 
  • Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy. 
  • Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. 
  • Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. 
  • Local cost structures and the economics of robot assisted radical prostatectomy. 
  • Locally advanced (high-risk) prostate cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort. 
  • Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml. 
  • Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. 
  • Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer. 
  • Loss of uteroglobin expression in prostate cancer: relationship to advancing grade. 
  • Low central venous pressure versus acute normovolemic hemodilution versus conventional fluid management for reducing blood loss in radical retropubic prostatectomy: a randomized controlled trial. 
  • MRS measured fatty acid composition of periprostatic adipose tissue correlates with pathological measures of prostate cancer aggressiveness. 
  • Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. 
  • Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. 
  • Management of male incontinence following artificial urinary sphincter failure. 
  • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. 
  • Management of patients with concurrent primary tumors of bladder and prostate. 
  • Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. 
  • Management of retained retractor during radical perineal prostatectomy. 
  • Managing Prostate Cancer Surgical Patients during the COVID-19 Pandemic: A Brief Report of the Duke Cancer Institute's Initial Experience. 
  • Maximizing outcomes in genitourinary cancers across the treatment continuum. 
  • Measuring costs in multisite randomized controlled trials: lessons from the VA Cooperative Studies Program. 
  • Mechanism of Action of the Transobturator Sling for Post-Radical Prostatectomy Incontinence: A Multi-institutional Prospective Study Using Dynamic Magnetic Resonance Imaging. 
  • Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. 
  • Minimally invasive open retropubic prostatectomy: in experienced hands--still the gold standard. 
  • Modeling recovery curves with application to prostatectomy. 
  • Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. 
  • Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. 
  • Monocyte counts and prostate cancer outcomes in white and black men: results from the SEARCH database. 
  • Mortality of patients after radical prostatectomy: analysis of recent Medicare claims. 
  • Most Gleason 8 Biopsies are Downgraded at Prostatectomy-Does 4 + 4 = 7? 
  • Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. 
  • Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. 
  • Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy. 
  • Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. 
  • Multimodal therapy of prostatic cancer. 
  • NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy. 
  • NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy. 
  • NCCN clinical practice guidelines in oncology: prostate cancer. 
  • Neoadjuvant androgen-deprivation therapy prior to radical prostatectomy: con. 
  • Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. 
  • Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. 
  • Neoadjuvant hormone therapy: the Canadian trials. 
  • Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. 
  • Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. 
  • New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer? 
  • Node-positive prostate cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging: proof of principle and initial clinical experience with extraprostatic extension. 
  • Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. 
  • Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans. 
  • Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. 
  • Obese men undergoing radical prostatectomy: Is robotic or retropubic better to limit positive surgical margins? Results from SEARCH. 
  • Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. 
  • Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. 
  • Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. 
  • Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. 
  • Obesity, race, and long-term prostate cancer outcomes. 
  • Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. 
  • Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. 
  • On-demand use of erectile aids in men with preoperative erectile dysfunction treated by whole gland prostate cryoablation. 
  • Open radical retropubic prostatectomy 2007: the true minimally invasive surgery for localized prostate cancer? 
  • Outcome analysis of urethral wall stent insertion with artificial urinary sphincter placement for severe recurrent bladder neck contracture following radical prostatectomy. 
  • Outcome profiles of locoregional disease after radical prostatectomy and radiotherapy. 
  • Outcome research: prostate cancer databases. 
  • Outcomes following artificial sphincter implantation after prior unsuccessful male sling. 
  • Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy. 
  • Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy. 
  • Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. 
  • PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. 
  • Pain management following robotic-assisted radical prostatectomy: transitioning to an opioid free regimen. 
  • Pathologic basis of focal therapy for early-stage prostate cancer. 
  • Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. 
  • Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. 
  • Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. 
  • Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. 
  • Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance. 
  • Patient reported incontinence after radical prostatectomy is more common than expected and not associated with the nerve sparing technique: results from the Center for Prostate Disease Research (CPDR) database. 
  • Patient selection for experimental adjuvant therapy after radical prostatectomy. 
  • Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. 
  • Pelvic muscle rehabilitation in males following prostatectomy. 
  • Penile shortening after radical prostatectomy and Peyronie's surgery. 
  • Percent tumor involvement and risk of biochemical progression after radical prostatectomy. 
  • Perineal seeding of prostate cancer as the only evidence of clinical recurrence 14 years after needle biopsy and radical prostatectomy: molecular correlation. 
  • Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer. 
  • Point: radical prostatectomy is the treatment of choice for high-risk prostate cancer patients. 
  • Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. 
  • Positive surgical margins at radical prostatectomy in the United States: Institutional variations and predictive factors. 
  • Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. 
  • Possible mechanism for seeding of tumor during radical prostatectomy. 
  • Post-radical prostatectomy management options for positive surgical margins: argument for observation. 
  • Post-treatment prostate MRI. 
  • Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens. 
  • Postoperative disseminated intravascular coagulation and fibrinolysis. 
  • Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. 
  • Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases. 
  • Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. 
  • Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule. 
  • Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: Results from the SEARCH database 
  • Postradical prostatectomy irradiation in carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. 
  • Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database. 
  • Predicting non-organ-confined prostate cancer in men diagnosed after 2000. 
  • Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. 
  • Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. 
  • Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database. 
  • Predictors of extracapsular extension and positive margins in African American and white men. 
  • Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy. 
  • Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. 
  • Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance. 
  • Preoperative predictors of pathologic stage T2a in low-risk prostate cancer: implications for focal therapy. 
  • Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy. 
  • Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. 
  • Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy. 
  • Prognosis of patients with stage D1 prostatic adenocarcinoma. 
  • Prospective evaluation of pain medication requirements and recovery after radical perineal prostatectomy. 
  • Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. 
  • Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance. 
  • Prostate cancer 1997--practicing what we preach. 
  • Prostate cancer assessment using MR elastography of fresh prostatectomy specimens at 9.4 T. 
  • Prostate cancer gene therapy. 
  • Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. 
  • Prostate cancer in the Baby Boomer generation: results from CaPSURE. 
  • Prostate cancer in young men: an important clinical entity. 
  • Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. 
  • Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. 
  • Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. 
  • Prostate cancer. 
  • Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994. 
  • Prostate cancer: ideal candidates for focal therapy. 
  • Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. 
  • Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. 
  • Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men. 
  • Prostate specific antigen only progression of prostate cancer. 
  • Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer. 
  • Prostate specific antigen recurrence after definitive therapy. 
  • Prostate specific antigen: a decade of discovery--what we have learned and where we are going. 
  • Prostate-specific antigen as a marker of disease activity in prostate cancer. 
  • Prostate-specific antigen as a marker of disease activity in prostate cancer. 
  • Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. 
  • Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. 
  • Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. 
  • Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. 
  • Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens. 
  • Prostatectomy vs brachytherapy for localized prostate cancer. 
  • Prostatic alpha-linolenic acid (ALA) is positively associated with aggressive prostate cancer: a relationship which may depend on genetic variation in ALA metabolism. 
  • Prostatic malignancy. 
  • Prostatic sarcoma with rapid tumor progression after nerve sparing radical cystoprostatectomy. 
  • Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. 
  • Proton-beam therapy after radical prostatectomy: Continued DVH idolatry? 
  • Psychosocial trajectories of men monitoring prostate-specific antigen levels following surgery for prostate cancer. 
  • Pubic Bone Osteomyelitis and Pubosymphyseal Urinary Fistula: A Poorly Recognized Complication in Prostate Cancer Survivors. 
  • RARP in high-risk prostate cancer: use of multi-parametric MRI and nerve sparing techniques. 
  • Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. 
  • Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. 
  • Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. 
  • Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort. 
  • Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients. 
  • Radical perineal prostatectomy. 
  • Radical perineal prostatectomy: a model for evaluating local response of prostate therapy. 
  • Radical perineal prostatectomy: oncological outcome during a 20-year period. 
  • Radical perineal vs. retropubic prostatectomy: a review of optimal application and technical considerations in the utilization of these exposures. 
  • Radical prostatectomy and cryotherapy--some answers, more questions. 
  • Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. 
  • Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. 
  • Radical prostatectomy in stage A prostatic adenocarcinoma. 
  • Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. 
  • Radical prostatectomy versus observation for localized prostate cancer. 
  • Radical prostatectomy versus radiation therapy for clinically localized prostate carcinoma: the butcher and the baker selling their wares. 
  • Radical prostatectomy versus radiation therapy: can pretreatment nomograms be used to select the appropriate prostate cancer treatment? 
  • Radical prostatectomy. 
  • Radical prostatectomy: anatomical predictors of success or failure. 
  • Radical prostatectomy: the pros and cons of the perineal versus retropubic approach. 
  • Radical prostatectomy: value of prostate MRI in surgical planning. 
  • Radical retropubic prostatectomy: the influence of accessory pudendal arteries on the recovery of sexual function. 
  • Radical surgery versus radiotherapy for adenocarcinoma of the prostate. 
  • Radiotherapy following radical prostatectomy. 
  • Radiotherapy for locally recurrent prostate cancer. 
  • Radiotherapy versus surgery for localized prostatic cancer. 
  • Randomized series of treatment with surgery versus radiation for prostate adenocarcinoma. 
  • Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. 
  • Re: Morbidity of radical perineal prostatectomy following transurethral resection of the prostate. 
  • Re: Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. 
  • Re: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. 
  • Re: Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy with Brachytherapy Boost and Disease Progression and Mortality in Patients with Gleason Score 9-10 Prostate Cancer. 
  • Re: The development of erectile dysfunction in men treated for prostate cancer. 
  • Re: Total prostatoseminal vesiculectomy in the treatment of debilitating perineal pain. 
  • Re: Transient lower extremity neurapraxia associated with radical perineal prostatectomy: a complication of the exaggerated lithotomy position. 
  • Reappraisal of radical perineal prostatectomy. 
  • Recent advances in the treatment of prostate cancer. 
  • Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. 
  • Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. 
  • Reply: To PMID 25432832. 
  • Resident involvement and experience do not affect perioperative complications following robotic prostatectomy. 
  • Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications. 
  • Response to Editorial Comment to Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy. 
  • Results of radical prostatectomy in men with clinically localized prostate cancer. 
  • Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. 
  • Revision rate after artificial urinary sphincter implantation for incontinence after radical prostatectomy: actuarial analysis. 
  • Rising PSA Level in an Anxious Postprostatectomy Patient. 
  • Rising PSA in nonmetastatic prostate cancer. 
  • Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. 
  • Robot-assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy. 
  • Robotic ultrasound and needle guidance for prostate cancer management: review of the contemporary literature. 
  • Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. 
  • SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. 
  • Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. 
  • Salvage radiation in men after prostate-specific antigen failure and the risk of death. 
  • Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. 
  • Seminal vesicle intraepithelial involvement by prostate cancer: putative mechanism and clinicopathological significance. 
  • Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database. 
  • Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. 
  • Serum lipid profiles and aggressive prostate cancer. 
  • Sexual Quality of Life and Satisfaction With Penile Prostheses. 
  • Sexual bother and function after radical prostatectomy: predictors of sexual bother recovery in men despite persistent post-operative sexual dysfunction. 
  • Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. 
  • Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. 
  • Single port robotic radical prostatectomy with the da Vinci SP platform: a step by step approach. 
  • Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. 
  • Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database. 
  • Staging lymphadenectomy should not be an antecedent to treatment in localized prostatic carcinoma. 
  • Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. 
  • Statin use and the risk of recurrence after radical prostatectomy in a cohort of men with inherited and/or early-onset forms of prostate cancer. 
  • Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. 
  • Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer. 
  • Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate-specific antigen levels. 
  • Stress urinary incontinence in the prostate cancer survivor. 
  • Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs. 
  • Successful outcome of artificial urinary sphincters in men with post-prostatectomy urinary incontinence despite adverse implantation features. 
  • Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. 
  • Surgical management of high-risk, localized prostate cancer. 
  • Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. 
  • Synchronous Surgical Management of Erectile Dysfunction and Stress Urinary Incontinence: A Systematic Review and Meta-Analysis of Reoperation Rates. 
  • Synchronous management of anastomotic contracture and stress urinary incontinence following radical prostatectomy. 
  • Systemic therapy for prostate cancer. 
  • The 17-Gene Genomic Prostate Score Test Is Prognostic for Outcomes After Primary External Beam Radiation Therapy in Men With Clinically Localized Prostate Cancer. 
  • The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). 
  • The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role? 
  • The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients. 
  • The Ohmmeter Identifies the Site of Fluid Leakage during Artificial Urinary Sphincter Revision Surgery. 
  • The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. 
  • The Stability of Physician-Specific Episode Costs for Urologic Cancer Surgery: Implications for Urologists Under the Merit-Based Incentive Program. 
  • The characteristics of bladder cancer after radiotherapy for prostate cancer. 
  • The clinical spectrum of prostate cancer. 
  • The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. 
  • The effect of intravenous indigo carmine on near-infrared cerebral oximetry. 
  • The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. 
  • The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. 
  • The immune response of the human brain to abdominal surgery. 
  • The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. 
  • The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. 
  • The male sling for stress urinary incontinence: tips and tricks for success. 
  • The management of strictures of the membranous urethra. 
  • The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. 
  • The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy. 
  • The relevance of stage A malignancy in prostatic cancer. 
  • The role of early adopter bias for new technologies in robot assisted laparoscopic prostatectomy. 
  • The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. 
  • The role of magnetic resonance imaging in delineating clinically significant prostate cancer. 
  • The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL. 
  • The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. 
  • The role of surgery in stage B-2 malignancy. 
  • The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. 
  • Three-dimensional localization and targeting of prostate cancer foci with imaging and histopathologic correlation: establishing a multidisciplinary team for quality improvement. 
  • Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. 
  • Time Trends in Use of Radical Prostatectomy by Tumor Risk and Life Expectancy in a National Veterans Affairs Cohort. 
  • Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. 
  • Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. 
  • Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. 
  • Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI. 
  • Tortuous and aberrant external iliac artery precluding radical retropubic prostatectomy for prostate cancer. 
  • Total prostatoseminal vesiculectomy in the treatment of debilitating perineal pain. 
  • Trainees do not negatively impact the institutional learning curve for robotic prostatectomy as characterized by operative time, estimated blood loss, and positive surgical margin rate. 
  • Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. 
  • Transcorporal artificial urinary sphincter cuff placement in cases requiring revision for erosion and urethral atrophy. 
  • Transdermal nicotine for analgesia after radical retropubic prostatectomy. 
  • Transient lower extremity neurapraxia associated with radical perineal prostatectomy: a complication of the exaggerated lithotomy position. 
  • Transient lumbosacral polyradiculopathy after prostatectomy: association with spinal stenosis. 
  • Treating the biochemical recurrence of prostate cancer after definitive primary therapy. 
  • Treatment Availability Influences Physicians' Portrayal of Robotic Surgery During Clinical Appointments. 
  • Treatment of locally confined prostatic cancer. Radiotherapy versus surgery: limits of curability. 
  • Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. 
  • Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. 
  • Ureteral reimplantation for inadvertent ureteral injury during radical perineal prostatectomy. 
  • Urinary continence and quality of life in the first year after radical perineal prostatectomy. 
  • Urinary outcomes are significantly affected by nerve sparing quality during radical prostatectomy. 
  • Urologic surgery. 
  • Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland. 
  • Use of Automated Performance Metrics to Measure Surgeon Performance during Robotic Vesicourethral Anastomosis and Methodical Development of a Training Tutorial. 
  • Use of Routine Home Health Care and Deviations From an Uncomplicated Recovery Pathway After Radical Prostatectomy. 
  • Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. 
  • Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients. 
  • Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. 
  • Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection. 
  • Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. 
  • Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. 
  • Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. 
  • Utilization of surgical procedures and racial disparity in the treatment of urinary incontinence after prostatectomy. 
  • Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. 
  • Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. 
  • Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer. 
  • Variables in predicting survival based on treating "PSA-only" relapse. 
  • Video urodynamics. 
  • What Should We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis? 
  • When should we pull the trigger for post-radical prostatectomy radiotherapy? 
  • When to diagnose and how to treat prostate cancer in the "not too fit" elderly. 
  • Will the future of health care lead to the end of the robotic golden years? 
  • Will the global economic downturn affect prostate cancer care? Pelvic lymphadenectomy as an example. 
  • Workshop summary: approaches to radical prostatectomy. 
  • Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation. 
  • p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. 
  • p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. 
• 

  Keywords of People

  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery, Urology